1. Search Result
Search Result
Results for "

glucagon

" in MedChemExpress (MCE) Product Catalog:

162

Inhibitors & Agonists

1

Screening Libraries

106

Peptides

3

Inhibitory Antibodies

6

Natural
Products

5

Recombinant Proteins

2

Isotope-Labeled Compounds

2

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19947

    glucagon receptor antagonists-4

    GCGR Metabolic Disease
    PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .
    PF-06291874
  • HY-P0082
    Glucagon (1-29), bovine, human
    5+ Cited Publications

    glucagon

    GCGR Metabolic Disease
    Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis . Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation .
    <em>Glucagon</em> (1-29), bovine, human
  • HY-50159

    GCGR Metabolic Disease
    Glucagon receptor antagonists-3 is a highly potent glucagon receptor antagonist.
    <em>Glucagon</em> receptor antagonists-3
  • HY-50158

    GCGR Metabolic Disease
    Glucagon receptor antagonists-2 is a highly potent glucagon receptor antagonist.
    <em>Glucagon</em> receptor antagonists-2
  • HY-P0082A

    glucagon hydrochloride

    GCGR Metabolic Disease
    Glucagon (1-29), bovine, human, porcine hydrochloride is a peptide hormone, produced by pancreatic α-cells. Glucagon hydrochloride stimulates gluconeogenesis . Glucagon (1-29), bovine, human, porcine hydrochloride activates HNF4α and increases HNF4α phosphorylation .
    <em>Glucagon</em> (1-29), bovine, human hydrochloride
  • HY-10036

    GCGR Metabolic Disease
    Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist.
    <em>Glucagon</em> receptor antagonists-1
  • HY-128781

    GCGR Metabolic Disease
    Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (Ki=32 nM). Glucagon receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM) .
    <em>Glucagon</em> receptor antagonists-5
  • HY-P0082R

    GCGR Metabolic Disease
    Glucagon (1-29), bovine, human (Standard) is the analytical standard of Glucagon (1-29), bovine, human. This product is intended for research and analytical applications. Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis . Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation .
    <em>Glucagon</em> (1-29), bovine, human (Standard)
  • HY-P0150

    GCGR Neurological Disease
    Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.
    <em>Glucagon</em> (19-29), human
  • HY-P1841

    Endogenous Metabolite Apoptosis Metabolic Disease
    Glucagon-Like Peptide (GLP) II, human is a 33-amino acid peptide derived from the C-terminal of proglucagon and mainly produced by the intestinal L cells. Glucagon-Like Peptide (GLP) II, human stimulates intestinal mucosal growth and decreases apoptosis of enterocytes .
    <em>Glucagon</em>-Like Peptide (GLP) II, human
  • HY-P1144

    glucagon-37 (bovine, porcine)

    GCGR Metabolic Disease
    Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .
    Oxyntomodulin (bovine, porcine)
  • HY-P1144A

    glucagon-37 (bovine, porcine) (TFA)

    GCGR Metabolic Disease
    Oxyntomodulin (bovine, porcine) TFA, a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .
    Oxyntomodulin (bovine, porcine) (TFA)
  • HY-P1145

    HuGLP-1

    GCGR Metabolic Disease
    Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.
    <em>Glucagon</em>-like peptide 1 (1-37), human
  • HY-P1145A

    HuGLP-1 TFA

    GCGR Metabolic Disease
    Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.
    <em>Glucagon</em>-like peptide 1 (1-37), human TFA
  • HY-P2535

    GLP Receptor Metabolic Disease
    Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human is an C-terminal-labelled biotinylated GLP-1 (7-36) amide.
    <em>Glucagon</em>-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human
  • HY-P5815

    glucagon-like Peptide 1 (1-36) amide (human, rat)

    GLP Receptor GCGR Metabolic Disease
    GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .
    GLP-1 (1-36) amide (human, rat)
  • HY-P5815A

    glucagon-like Peptide 1 (1-36) amide (human, rat) (TFA)

    GLP Receptor GCGR Metabolic Disease
    GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .
    GLP-1 (1-36) amide (human, rat) (TFA)
  • HY-P1024

    GLP-2 (human); glucagon-like peptide 2 (human)

    GCGR Metabolic Disease
    GLP-2(1-33) (human) is an enteroendocrine hormone which can bind to the GLP-2 receptor and stimulate the growth of intestinal epithelium.
    GLP-2(1-33)(human)
  • HY-P0054
    GLP-1(7-36), amide acetate
    5+ Cited Publications

    glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate

    GCGR Metabolic Disease
    GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
    GLP-1(7-36), amide acetate
  • HY-P0054A

    glucagon-like peptide-1 (GLP-1)(7-36), amide; Human GLP-1 (7-36), amide

    GCGR Metabolic Disease
    GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.
    GLP-1(7-36), amide
  • HY-P0054B
    GLP-1(7-36), amide TFA
    5+ Cited Publications

    glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA

    GCGR Metabolic Disease
    GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .
    GLP-1(7-36), amide TFA
  • HY-P1143

    GCGR Metabolic Disease
    [Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .
    [Des-His1,Glu9]-<em>Glucagon</em> amide
  • HY-P1143A

    GCGR Metabolic Disease
    [Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .
    [Des-His1,Glu9]-<em>Glucagon</em> amide TFA
  • HY-P3608

    GCGR Metabolic Disease
    [Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .
    [Des-His1,Glu9] <em>Glucagon</em>
  • HY-P4672

    GCGR Metabolic Disease
    (Met(O)27)-Glucagon (1-29) (human, rat, porcine) is a modified glucagon. (Met(O)27)-Glucagon (1-29) (human, rat, porcine) has the same maximum glucose-synthesizing activity in rat hepatocytes as native glucagon, but it is less potent, suggesting a crucial role of methionine in the binding of glucagon to its hepatic receptor .
    (Met(O)27)-<em>Glucagon</em> (1-29) (human, rat, porcine)
  • HY-P3621

    GCGR Metabolic Disease
    Biotinyl-Glucagon (1-29), human, bovine, porcine is a biotinylated glucagon. Glucagon is a peptide hormone, produced by α-cells of the pancreas, can increase concentration of glucose and fatty acids in the bloodstream .
    Biotinyl-<em>Glucagon</em> (1-29), human, bovine, porcine
  • HY-P3616

    GCGR Metabolic Disease
    Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide is a biotin labeled glucagon-like peptide-1-(7-36). Glucagon-like peptide-1-(7-36) is a gastrointestinal peptide with antidiabetogenic activity, and can increase the release of insulin .
    Human <em>glucagon</em>-like peptide-1-(7-36)-Lys(Biotin) amide
  • HY-P3623

    Fluorescent Dye Others
    Biotin-Glucagon-Like Peptide 1 (7-36) amide, human is a biologically active peptide. Biotin-Glucagon-Like Peptide 1 (7-36) amide, human can be used for the research of various biochemical studies.
    Biotin-<em>Glucagon</em>-Like Peptide 1 (7-36) amide, human
  • HY-12525

    GCGR Metabolic Disease
    LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research .
    LGD-6972
  • HY-108614

    Others Metabolic Disease
    GPi688 is a potent and orally active glycogen phosphorylase (GPa) inhibitor with IC50s of 19 nM, 61 nM and 12 nM for human liver GPa, rat liver GPa and human skeletal muscle GPa, respectively . GPi688 can inhibit glucagons-mediated glucose output in rat primary hepatocytes. GPi688 can be used for researching glucagon-mediated hyperglycaemia .
    GPi688
  • HY-119739

    GCGR Metabolic Disease Cancer
    Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective glucagon antagonist. Skyrin can inhibit the growth of tumor cells .
    Skyrin
  • HY-P10327

    GLP Receptor Metabolic Disease
    PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC50 values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR .
    PP18
  • HY-P5161A

    GCGR Metabolic Disease
    FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .
    FC382K10W15 TFA
  • HY-P10302

    GLP Receptor Insulin Receptor Metabolic Disease
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R/GIPR agonist-1
  • HY-142114

    Others Metabolic Disease
    SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes .
    SRI-37330
  • HY-P1871A

    Amylin Receptor Metabolic Disease
    Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .
    Amylin (IAPP), feline TFA
  • HY-P3506

    LY3437943

    GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
    Retatrutide
  • HY-P3506B

    LY3437943 acetate

    GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
    Retatrutide acetate
  • HY-P1871

    Amylin Receptor Metabolic Disease
    Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .
    Amylin (IAPP), feline
  • HY-P3506A

    LY3437943 TFA

    GLP Receptor GCGR Metabolic Disease
    Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
    Retatrutide TFA
  • HY-P1070

    DAP amide, human

    Amylin Receptor Metabolic Disease
    Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .
    Amylin, amide, human
  • HY-P1070A

    DAP amide, human TFA

    Amylin Receptor Metabolic Disease
    Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .
    Amylin, amide, human TFA
  • HY-14292

    Dipeptidyl Peptidase Metabolic Disease
    NVP-DPP728 is a potent, reversible and nitrile-dependent dipeptidyl peptidase IV (DPP-IV) inhibitor. NVP-DPP728 can inhibit human DPP-IV amidolytic activity with a Ki of 11 nM. NVP-DPP728 inhibits degradation of glucagon-like peptide-1 (GLP-1) and thereby potentiates insulin release in response to glucose intake. NVP-DPP728 can be used for researching diabetes .
    NVP-DPP728
  • HY-P3375

    IBI-362; LY-3305677; OXM-3

    GCGR GLP Receptor Metabolic Disease
    Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .
    Mazdutide
  • HY-P3375A

    IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA

    GCGR GLP Receptor Metabolic Disease
    Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .
    Mazdutide TFA
  • HY-50675

    GCGR Metabolic Disease
    GRA Ex-25 is an inhibitor of glucagon receptor, with IC50 of 56 and 55 nM for rat and human glucagon receptors, respectively.
    GRA Ex-25
  • HY-P4146

    BI 456906

    GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-P4146A

    BI 456906 TFA

    GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA
  • HY-164040

    Somatostatin Receptor Metabolic Disease
    Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC50 <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .
    Zavolosotine
  • HY-103547

    GCGR Metabolic Disease
    L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC50s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively .
    L-168049

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: